Ziconotide

Product Name: Ziconotide

Form: Free base

CAS No: 107452-89-1

Molar Mass: 2639.13

Chemical Formula: C102H172N36O32S7

Synonyms: SNX-111

Storage: Store at -20℃

Sequence: CKGKGAKCSRLMYDCCTGSCRSGKC-NH2

Target: N-type calcium channel

Application:

Ziconotide (CAS: 107452-89-1) is a synthetic peptide-based analgesic used in the management of severe chronic pain, particularly neuropathic pain. It functions by selectively blocking N-type voltage-gated calcium channels (VGCCs) in the central nervous system, inhibiting the release of neurotransmitters such as glutamate and substance P. This blockade attenuates pain signaling pathways, leading to pain relief. Ziconotide is administered intrathecally, directly into the cerebrospinal fluid, to target pain transmission in the spinal cord. In pharmaceutical chemistry, ziconotide's targeted inhibition of N-type calcium channels represents a significant advancement in the treatment of refractory chronic pain, offering a specific and effective therapeutic option for patients with neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia. Its application underscores its importance in pain management and improving quality of life for individuals with debilitating pain conditions. Additionally, ongoing research explores ziconotide's potential in other pain disorders and its role in combination therapies, highlighting its versatility in analgesic therapeutics.

Current Research:

Ziconotide is a synthetic peptide and a potent N-type calcium channel blocker used in the management of severe, chronic pain, particularly in patients who are intolerant or unresponsive to other pain management therapies. Derived from the cone snail Conus magus, ziconotide acts by inhibiting calcium influx through N-type voltage-gated calcium channels, which are primarily involved in the release of neurotransmitters related to pain signaling in the central nervous system. Its mechanism of action makes it particularly effective for targeting neuropathic pain and in cases of severe, refractory pain that cannot be controlled by oral medications or other conventional treatments.

Mechanism of Action
Ziconotide works by binding to and inhibiting N-type calcium channels, which are expressed in high concentrations in neurons of the spinal cord and other regions of the central nervous system. These channels play a key role in the release of neurotransmitters, including substance P and glutamate, which are involved in pain transmission. By blocking these channels, ziconotide reduces the release of pain-mediating neurotransmitters, thereby decreasing the perception of pain. Unlike opioid analgesics, ziconotide does not affect the opioid receptors, and it is not associated with the risk of tolerance, dependence, or overdose typically seen with opioids. Ziconotide's action is localized primarily to the spinal cord, making it particularly effective for managing neuropathic pain without the systemic side effects that can occur with oral medications.

Indications and Uses
Ziconotide is indicated for the treatment of severe chronic pain in patients who are refractory to or unable to tolerate conventional therapies, including opioids. It is typically administered via intrathecal injection (directly into the spinal fluid) and is used in patients who require long-term, continuous pain management, particularly those with conditions such as cancer pain, neuropathic pain, and other types of intractable pain. Ziconotide is not intended for use in patients with mild to moderate pain or for short-term use. Due to its delivery method, it is often considered a treatment of last resort in patients who have exhausted other pain management options.

Efficacy and Clinical Benefits
Clinical studies have demonstrated that ziconotide can provide significant relief for patients with severe, chronic pain that is not responsive to oral analgesics or other pain management strategies. Ziconotide has been shown to reduce pain intensity and improve quality of life in patients with neuropathic pain, including those with conditions such as failed back surgery syndrome and cancer pain. When administered intrathecally, ziconotide achieves direct targeting of pain pathways in the spinal cord, leading to faster onset and more effective pain relief compared to systemic medications. Moreover, its use does not carry the same risks as opioid medications, such as addiction or respiratory depression, making it a valuable alternative for long-term pain management.

Safety and Tolerability
Ziconotide is generally well tolerated, but it is associated with several potential side effects. The most common side effects include dizziness, nausea, headache, and cognitive or neurological effects such as confusion, memory problems, or mood changes. Because it is administered intrathecally, it can cause issues related to the injection site, including infection, inflammation, or catheter-related complications. Additionally, some patients may experience psychiatric side effects, including depression or hallucinations, especially at higher doses. Unlike opioids, ziconotide does not cause physical dependence or withdrawal symptoms, but it is important to monitor patients for adverse neurological effects. The most significant safety concern is the potential for overdose or toxicity if the drug is administered incorrectly or at too high a dose, which can result in severe neurological effects.

Advantages and Limitations
One of the major advantages of ziconotide is its ability to provide targeted pain relief through intrathecal administration, which allows for higher concentrations of the drug at the site of pain transmission with minimal systemic exposure. This can be particularly beneficial for patients with severe, chronic pain who have not found relief through oral or other systemic therapies. Ziconotide does not carry the same risk of opioid-related side effects such as respiratory depression, tolerance, or addiction, making it an attractive alternative for patients who cannot tolerate or do not respond to opioids. However, its administration via intrathecal injection requires specialized equipment and expertise, and not all patients are candidates for this delivery method. Additionally, ziconotide can cause neurological and psychiatric side effects, which may limit its use in some individuals.

Future Directions
Ongoing research into ziconotide is focused on improving its delivery methods and expanding its therapeutic uses. Studies are investigating the potential benefits of combining ziconotide with other analgesics or adjuvant therapies to enhance its pain-relieving effects. Research is also exploring its use in treating other conditions involving neuropathic pain, such as postherpetic neuralgia, multiple sclerosis, and diabetic neuropathy. Furthermore, efforts to optimize its dosing regimen and minimize side effects are critical for improving its tolerability and expanding its use in a broader patient population. The development of alternative delivery systems, such as non-invasive methods, may also improve patient access and adherence to treatment.

Reference:

Williams, J. A., Day, M., & Heavner, J. E. (2008). Ziconotide: an update and review. Expert opinion on pharmacotherapy, 9(9), 1575-1583.

Sorrieul, J., Robert, J., Blanchet, A., Gouju, J., Bienfait, F., Hamon, S. J., … & Devys, C. (2024). Physicochemical Stability Study of the Morphine-Bupivacaine-Ziconotide Association. Neuromodulation: Technology at the Neural Interface.